Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
posted on 2019-08-28, 10:27authored byBH Rovin, DJ Caster, DC Cattran, KL Gibson, JJ Hogan, MJ Moeller, D Roccatello, M Cheung, DC Wheeler, WC Winkelmayer, J Floege, Conference Participants
In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.
Funding
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.
History
Citation
Kidney International, 2019, 95 (2), pp. 281-295
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation
SUPPLEMENTARY MATERIAL
Table S1. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
glomerulonephritis (GN) guideline recommendations related to
minimal change disease, focal segmental glomerulosclerosis (FSGS),
steroid-sensitive nephrotic syndrome (SSNS), and steroid-resistant
nephrotic syndrome (SRNS): Need to be revisited?
Table S2. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
glomerulonephritis (GN) guideline recommendations related to
idiopathic membranoproliferative glomerulonephritis: Need to be
revisited?
Table S3. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
glomerulonephritis (GN) guideline recommendations related to lupus
nephritis: Need to be revisited?
Table S4. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
glomerulonephritis (GN) guideline recommendations related to antineutrophil cytoplasmic antibody–associated vasculitis (AAV): Need to
be revisited?
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.